(Values in U.S. Thousands) | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 | Dec, 2019 |
Sales | 0 | 710 | 1,810 | 860 | 740 |
Sales Growth | -100.00% | -60.77% | +110.46% | +16.22% | -98.70% |
Net Income | -614,930 | -78,780 | -88,600 | -52,700 | -29,130 |
Net Income Growth | -680.57% | +11.08% | -68.12% | -80.91% | -391.59% |
Summit Therapeu ADR (SMMT)
18.19 -0.01 (-0.05%) 01/16/25 [NASDAQ]
17.85 x 1,000 18.29 x 300
Realtime by (Cboe BZX)
17.85 x 1,000 18.29 x 300
Realtime 18.29 +0.10 (+0.55%) 17:19 ET
for Thu, Jan 16th, 2025
Summit Therapeutics PLC is engaged in the discovery and development of drug to treat the fatal muscle wasting disease Duchenne Muscular Dystrophy and infections caused by the bacteria C. difficile. Summit Therapeutics PLC is headquartered in Abingdon, the United Kingdom.
Fiscal Year End Date: 12/31